Navigation Links
Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine

reditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four gene-based therapies and DNA vaccines in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical, with the industry's most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology and about the availability of supporting internet technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans); the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism; the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop; evaluation of potential opportunities; issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies; whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
4. Inovio: DNA delivery technology shows positive human results
5. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Post Your Comments:
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Medical, Inc. announces the addition of the BioTech Medical ... to its ever expanding line of innovative ... goes by that our office doesn,t receive a call for ... BioTech Medical, Inc.  "We listened to our customers, and now, ...
... Md., July 18, 2011 MedImmune announced today ... Live, Intranasal) to influenza vaccine distributors who service ... MedImmune expects to provide approximately 15 ... spray flu vaccine for the 2011-2012 influenza season ...
Cached Medicine Technology:FluMist® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season 2FluMist® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season 3
(Date:10/2/2014)... Philadelphia, PA (PRWEB) October 02, 2014 ... winners of the 2014 BIG Awards for Business ... companies and organizations with a proprietary judging process ... from around the globe. , “The winners this ... said Russ Fordyce, Managing Director of the Business ...
(Date:10/2/2014)... Salamon HealthDay Reporter ... with a neurotic personality style and prolonged stress may ... research suggests. Tracking 800 women over nearly four ... anxious, jealous and moody -- which they defined as ... risk of developing Alzheimer,s compared to women scoring lowest ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... and British scientists have now found that it is helpful in ... warfare. , ... Manhasset, NY (Vocus) May 6, 2009 ... found that it is helpful in delaying the effects of ricin, ...
... May 6 Parishioners at Guardian Angels Catholic Church in ... shelf -- they actually grow it themselves. The project is ... by the Institute for Agriculture and Trade Policy (IATP) and ... Cross) that demonstrate a growing nationwide movement within the faith ...
... 6 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that Brian ... Hite, Senior Vice President and Chief Financial Officer, are scheduled ... 2009 Healthcare Conference at the Palace Hotel in New York ...
... Mich., May 6 Perrigo Company (Nasdaq: ... Directors declared a quarterly dividend of $0.055 per share, ... on May 29, 2009. Perrigo Company is a leading ... (OTC) and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
... PA, 6 May 2009 Obstructive sleep apnea (OSA) ... in heart failure (HF) patients managed with beta-blockers and ... Journal of Cardiac Failure ( http://www.elsevier.com/locate/cardfail ), ... of Sleep Apnea in Patients with Heart Failure and ...
... lack of guidance and training provided for nurses involved in ... , Writing in the May issue of the Journal ... highlighted the need for an audit of current UK services ... , But they point out that the basic issues they ...
Cached Medicine News:Health News:Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 3Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 4Health News:Symmetry Medical to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference 2Health News:Sleep apnea may not be closely linked to heart failure severity 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: